Loading
Bladder and Urothelial Cancer Treatments · Journal article
Cancer Immunology Research · August 11, 2026
Encouraging direction, but not yet definitive.
This cross-sectional study identifies MFAP2+ cancer-associated fibroblasts as a pre-treatment microenvironment marker associated with BCG immunotherapy failure in early-stage bladder cancer, proposing a stepwise immune evasion model. The findings are mechanistically interesting and offer potential for response prediction, but lack prospective validation or quantified effect sizes to establish clinical utility.
Cross-sectional mechanistic analysis. Early-stage bladder cancer patients treated with BCG adjuvant therapy. Intervention: BCG adjuvant immunotherapy.
BCG response did not correlate with the number of tumor-infiltrating T cells but was determined by pre-treatment immunosuppressive microenvironment MFAP2+ CAF subset impairs BCG-induced antitumoral immunity by interacting with T cells and tertiary lymphoid structures Stepwise activation of immune evasion factors: increasing MFAP2+ CAF to PD-L1 activation to LAG3 on T cells during early-stage BCa development
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If prospectively validated, MFAP2+ CAF status could enable patient stratification to identify BCG non-responders and guide alternative treatment strategies. Current evidence is insufficient to recommend clinical implementation without independent validation.
A mechanistic study identifying a novel immunosuppressive microenvironment biomarker (MFAP2+ CAF) associated with BCG failure in bladder cancer, based on patient tumour analysis with potential for predicting response, but lacking validation in a prospective cohort or clinical trial.
As stated by the source record.
Quoted from the source exactly as published.
If prospectively validated, MFAP2+ CAF status could enable patient stratification to identify BCG non-responders and guide alternative treatment strategies. Current evidence is insufficient to recommend clinical implementation without independent validation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Bacillus Calmette-Guérin (BCG) is the standard adjuvant therapy for early-stage bladder cancer (BCa), based on its immunostimulatory activity. However, over half of patients experience BCG failure and subsequent recurrence. The heterogeneity of the tumor microenvironment may influence BCG response, however this relationship is currently not well-established. We found that BCG response did not correlate with the number of tumor-infiltrating T cells but was determined by the pre-treatment immunosuppressive microenvironment. We identified a subset of cancer-associated fibroblasts characterized by microfibrillar-associated protein 2 (MFAP2+ CAF), which impaired BCG-induced antitumoral immunity by interacting with both individual T cells and tertiary lymphoid structures/lymphoid aggregates. This study also revealed a potential stepwise activation of cancer immune evasion factors based on cross-sectional analysis, from increasing MFAP2+ CAF to activation of PD-L1 and then LAG3 on T cells, during early-stage BCa development. These findings have the potential to enable accurate prediction of BCG response. This approach may also be applicable to the investigation of other human cancers.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.